Eris Lifesciences
Eris Lifesciences Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in Eris Lifesciences
Start SIPEris Lifesciences Investment Rating
-
Master Rating:
-
Eris Lifesciences has an operating revenue of Rs. 1,588.30 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of 33% is great, ROE of 21% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 65 which is a FAIR score but needs to improve its earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at C- which is evident from recent supply seen, Group Rank of 153 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of C is fair but needs to improve. Overall, the stock has mediocre earnings and technical strength, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|
| Oper Rev Qtr Cr | 327 | 350 | 322 | 277 |
| Operating Expenses Qtr Cr | 206 | 214 | 203 | 181 |
| Operating Profit Qtr Cr | 126 | 141 | 126 | 102 |
| Depreciation Qtr Cr | 16 | 16 | 15 | 15 |
| Interest Qtr Cr | 3 | 7 | 7 | 1 |
| Tax Qtr Cr | 11 | 9 | 12 | 8 |
| Net Profit Qtr Cr | 99 | 115 | 96 | 87 |
Eris Lifesciences Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 16
- 20 Day
- 602.76
- 50 Day
- 623.64
- 100 Day
- 642.93
- 200 Day
- 661.7
- 20 Day
- 611.1
- 50 Day
- 625.51
- 100 Day
- 650.49
- 200 Day
- 667.81
Eris Lifesciences Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 574.67 |
| Second Resistance | 581.39 |
| Third Resistance | 586.07 |
| RSI | 23.56 |
| MACD Single Line | -11.82 |
| MACD | -17.22 |
| Support | |
|---|---|
| First Resistance | 563.27 |
| Second Resistance | 558.59 |
| Third Resistance | 551.87 |
Eris Lifesciences Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 61,333 | 4,641,068 | 75.67 |
| Week | 562,969 | 43,010,862 | 76.4 |
| 1 Month | 150,642 | 11,254,467 | 74.71 |
| 6 Month | 80,162 | 5,550,417 | 69.24 |
Eris Lifesciences Result Highlights
Eris Lifesciences Synopsis
NSE-Medical-Biomed/Biotech
Eris Lifesciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 1215.73 Cr. and Equity Capital is Rs. 13.59 Cr. for the Year ended 31/03/2022. Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867.| Market Cap | 7,730 |
| Sales | 1,298 |
| Shares in Float | 6.39 |
| No of funds | 115 |
| Yield | 1.29 |
| Book Value | 4.03 |
| U/D Vol ratio | 0.3 |
| LTDebt / Equity | |
| Alpha | -0.08 |
| Beta | 0.33 |
Eris Lifesciences
| Owner Name | Dec-22 | Sep-22 | Jun-22 | Mar-22 |
|---|---|---|---|---|
| Promoters | 52.7% | 52.29% | 52.3% | |
| Mutual Funds | 9.64% | 10.38% | 10.36% | |
| Foreign Portfolio Investors | 15.5% | 15.39% | 15.35% | |
| Financial Institutions/ Banks | ||||
| Individual Investors | 21.45% | 21.26% | 21.34% | |
| Others | 0.71% | 0.68% | 0.65% |
Eris Lifesciences Management
| Name | Designation |
|---|---|
| Mr. Amit Bakshi | Chairperson & Managing Director |
| Mr. Krishnakumar Vaidyanathan | COO & Executive Director |
| Mr. Inderjeet Singh Negi | Executive Director |
| Mr. Kaushal Shah | Executive Director |
| Mr. Rajeev Dalal | Independent Director |
| Mr. Vasudevan Sujesh | Independent Director |
| Ms. Kalpana Unadkat | Independent Director |
| Mr. Prashant Gupta | Independent Director |
Eris Lifesciences Forecast
Price Estimates
Eris Lifesciences FAQs
What is Share Price of Eris Lifesciences ?
Eris Lifesciences share price is ₹568 As on 23 March, 2023 | 07:52
What is the Market Cap of Eris Lifesciences ?
The Market Cap of Eris Lifesciences is ₹7729.8 Cr As on 23 March, 2023 | 07:52
What is the P/E ratio of Eris Lifesciences ?
The P/E ratio of Eris Lifesciences is 19.5 As on 23 March, 2023 | 07:52
What is the PB ratio of Eris Lifesciences ?
The PB ratio of Eris Lifesciences is 4.1 As on 23 March, 2023 | 07:52